UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

HCV epidemiology in high-risk groups and the risk of reinfection

Journal of hepatology, 2016-10, Vol.65 (1), p.S33-S45

2016

Volltextzugriff (PDF)

CMV drives clonal expansion of NKG2C+ NK cells expressing self‐specific KIRs in chronic hepatitis patients

European journal of immunology, 2012-02, Vol.42 (2), p.447-457

2012

Volltextzugriff (PDF)

Hepatitis C reinfection after sustained virological response

Journal of hepatology, 2016-05, Vol.64 (5), p.1020-1026

2016

Volltextzugriff (PDF)

Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County

BMC infectious diseases, 2019-11, Vol.19 (1), p.955-955, Article 955

2019

Volltextzugriff (PDF)

Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study

PloS one, 2017-07, Vol.12 (7), p.e0179764-e0179764

2017

Volltextzugriff (PDF)

Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial

Trials, 2020-06, Vol.21 (1), p.485-485, Article 485

2020

Volltextzugriff (PDF)

Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection

PloS one, 2016-05, Vol.11 (5), p.e0155142-e0155142

2016

Volltextzugriff (PDF)

The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection

PloS one, 2015-08, Vol.10 (8), p.e0120866-e0120866

2015

Volltextzugriff (PDF)

Health-related quality of life in patients with different stages of liver disease induced by hepatitis C

Scandinavian journal of gastroenterology, 2009, Vol.44 (7), p.878-887

2009

Volltextzugriff (PDF)

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial

Annals of internal medicine, 2016-11, Vol.165 (9), p.625

2016

Volltextzugriff (PDF)

Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV)

BMC infectious diseases, 2019-11, Vol.19 (1), p.943-9, Article 943

2019

Volltextzugriff (PDF)

Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial

Annals of internal medicine, 2021-09, Vol.174 (9), p.1261

2021

Volltextzugriff (PDF)

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

Hepatology (Baltimore, Md.), 2011-03, Vol.53 (3), p.746-754

2011

Volltextzugriff (PDF)

Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugs

The International journal of drug policy, 2024-01, Vol.123, p.104279-104279, Article 104279

2024

Volltextzugriff (PDF)

All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: A controlled study

Journal of hepatology, 2013-01, Vol.58 (1), p.31-37

2013

Volltextzugriff (PDF)

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

The lancet. Gastroenterology & hepatology, 2018-03, Vol.3 (3), p.153-161

2018

Volltextzugriff (PDF)

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study

Hepatology (Baltimore, Md.), 2004-12, Vol.40 (6), p.1260-1265

2004

Volltextzugriff (PDF)

High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway

Scandinavian journal of gastroenterology, 2023-03, Vol.58 (3), p.264-268

2023

Volltextzugriff (PDF)

Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study

The International journal of drug policy, 2023-06, Vol.116, p.104044-104044, Article 104044

2023

Volltextzugriff (PDF)

Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study

Journal of hepatology, 2014-02, Vol.60 (2), p.260-266

2014

Volltextzugriff (PDF)

Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse

Journal of clinical virology, 2017-07, Vol.92, p.32-38

2017

Volltextzugriff (PDF)

HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984

Scandinavian journal of gastroenterology, 2014-12, Vol.49 (12), p.1465-1472

2014

Volltextzugriff (PDF)

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study

The International journal of drug policy, 2017-09, Vol.47, p.230-238

2017

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

KollektionOxford University Press Journals Current

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(35)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(35)
Female
(34)
Science & Technology
(31)
Adult
(29)
Life Sciences & Biomedicine
(28)
Middle Aged
(26)
Hepacivirus - Genetics
(18)
Hepatitis C, Chronic - Drug Therapy
(18)
Antiviral Agents - Therapeutic Use
(16)
Gastroenterology & Hepatology
(16)
Hepatitis C
(14)
Genotype
(12)
Drug Therapy, Combination
(11)
Treatment Outcome
(11)
Hepatitis C Virus
(10)
Hepatitis C, Chronic - Virology
(10)
Recurrence
(10)
Substance Abuse, Intravenous - Complications
(10)
Gastroenterology And Hepatology
(9)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

HCV epidemiology in high-risk groups and the risk of reinfection

CMV drives clonal expansion of NKG2C+ NK cells expressing self‐specific KIRs in chronic hepatitis patients

Hepatitis C reinfection after sustained virological response

Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County

Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study

Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial

Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection

The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection

Health-related quality of life in patients with different stages of liver disease induced by hepatitis C

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial

Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV)

Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

Towards elimination of hepatitis C in Oslo: Cross-sectional prevalence studies among people who inject drugs

All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: A controlled study

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study

High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway

Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study

Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: A longitudinal long-term cohort study

Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse

HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984

Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy

Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study

Aktive Filter

Suchergebnisse filtern